OOIR: Observatory of International Research

Papers

(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	733
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	423
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	109
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	106
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	96
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	82
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	79
Herpes zoster and dementia : more evidences for a causal link	68
Gene and genetic therapies in Alzheimer’s disease and other dementias	60
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	50
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	47
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	46
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	41
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	38
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	38
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	38
Informal care for people with dementia in Europe	37
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	37
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	36
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	36
Introduction to the Special Issue on the A4 Study	32
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	30
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	30
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	27
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	26

Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review